Dupixent is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Sanofi-aventis U.s. Llc. The primary component is Dupilumab.
Product ID | 0024-5914_0495c7d4-a900-4b9a-8e7a-8828382c4e7d |
NDC | 0024-5914 |
Product Type | Human Prescription Drug |
Proprietary Name | Dupixent |
Generic Name | Dupilumab |
Dosage Form | Injection, Solution |
Route of Administration | SUBCUTANEOUS |
Marketing Start Date | 2017-03-28 |
Marketing Category | BLA / BLA |
Application Number | BLA761055 |
Labeler Name | sanofi-aventis U.S. LLC |
Substance Name | DUPILUMAB |
Active Ingredient Strength | 300 mg/2mL |
Pharm Classes | Antibodies, Monoclonal [CS], Interleukin 4 Receptor alpha Antagonists [MoA], Interleukin-4 Receptor alpha Antagonist [EPC] |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2017-03-28 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | BLA |
Application Number | BLA761055 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2017-03-28 |
Marketing Category | BLA |
Application Number | BLA761055 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2018-07-01 |
Ingredient | Strength |
---|---|
DUPILUMAB | 300 mg/2mL |
SPL SET ID: | 595f437d-2729-40bb-9c62-c8ece1f82780 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
0024-5911 | Dupixent | Dupilumab |
0024-5914 | Dupixent | Dupilumab |
0024-5915 | Dupixent | Dupilumab |
0024-5916 | Dupixent | Dupilumab |
0024-5918 | Dupixent | Dupixent |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
DUPIXENT 97429846 not registered Live/Pending |
Sanofi Biotechnology 2022-05-26 |
DUPIXENT 87202613 5235634 Live/Registered |
Sanofi Biotechnology 2016-10-13 |
DUPIXENT 86807623 4978127 Live/Registered |
Sanofi Biotechnology 2015-11-03 |